NCT01545141 - Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

April 8, 2016

Study Completion Date

April 8, 2017

Conditions

Colorectal CancerColorectal CarcinomaColorectal TumorsNeoplasms, Colorectal

Interventions

DRUG

Chemokin Modulatory Regimen (5 MU/m2)

Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.

DRUG

Chemokin Modulatory Regimen (10 MU/m2)

Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery

DRUG

Chemokin Modulatory Regimen (20 MU/m2)

Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery

Trial Locations (1)

15232

UPMC Hillman Cancer Center, Pittsburgh